Tech Company Financing Transactions
SutroVax Funding Round
On 7/24/2015, SutroVax landed $22 million in Series A funding from Abingworth, CTI Life Sciences Fund and Longitude Capital Management.
Transaction Overview
Company Name
Announced On
7/24/2015
Transaction Type
Venture Equity
Amount
$22,000,000
Round
Series A
Investors
Abingworth (Lead Investor) (Kurt Emster)
Proceeds Purpose
SutroVax will use the funds to advance multiple vaccines in its pipeline through pre-clinical proof of concept.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
353 Hatch Dr.
Foster City, CA 94404
USA
Foster City, CA 94404
USA
Phone
Website
Email Address
Overview
SutroVax is an independent vaccine platform and development company that was spun-out of Sutro Biopharma. The company will leverage Sutro's Xpress CF and Xpress CF+ platforms for cell-free protein synthesis and site-specific conjugation to develop novel vaccines for an array of disease targets.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Grant Pickering
Chief Medical Officer
Alan Kimura
Chief Operating Officer
James Wassil
VP - General Counsel
Jane Mitchell
VP - Manufacturing
Paul Sauer
VP - R & D
Jeff Fairman
Browse more venture capital transactions:
Prev: 7/24/2015: ZVerse venture capital transaction
Next: 7/24/2015: Outpost Games venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs